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Abstract
Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer’s disease (AD) treatment but the
clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce
pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group
demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF
therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we
exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory
Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that
‘‘painless’’ hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive
activity in vivo. When administered intranasally to APPxPS1 mice ( n=8), hNGFP61S/R100E prevents the progress of
neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-
amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of ‘‘painless’’ hNGF
variants as a new generation of therapeutics for neurodegenerative diseases.
Citation: Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, et al. (2012) Intranasal ‘‘painless’’ Human Nerve Growth Factors Slows Amyloid Neurodegeneration
and Prevents Memory Deficits in App X PS1 Mice. PLoS ONE 7(5): e37555. doi:10.1371/journal.pone.0037555
Editor: Gemma Casadesus, Case Western Reserve University, United States of America
Received December 29, 2011; Accepted April 25, 2012; Published May 30, 2012
Copyright:  2012 Capsoni et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was supported by: Ministero Universita’ e Ricerca (Project RBAP10L8TY) and Italian Institute of Technology (EBRI/IIT project). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: antonino.cattaneo@sns.it
Introduction
Nerve Growth Factor (NGF) [1] has a considerable therapeutic
potential for Alzheimer’s disease (AD), not merely as a long-lasting
cholinergic maintenance [2,3,4] and neuroprotective agent [5,6],
but also as a direct anti-amyloidogenic factor [7,8]. However, the
development of an NGF-based therapy for neurodegenerative
diseases remains a considerable challenge [9], due to limited access
of NGF to the brain [10] and to its potent nociceptive actions in
animals and humans [11,12].
Current strategies for NGF therapy in AD use highly invasive
approaches, such as a neurosurgical intracerebroventricular in-
jection of NGF [13] or a parenchimal injection of cells secreting
hNGF (human NGF) [14] or of viruses harboring hNGF gene
[15].
To fully exploit the therapeutic potential of NGF in a non-
invasive manner, its therapeutic window must be improved, by
increasing the brain distribution, while limiting NGF pain-
inducing actions [7]. The intranasal delivery [16] represents
a viable option to non invasively increase NGF biodistribution in
the brain [17], where it exerts anti-neurodegenerative actions
[18,19,20]. NGF intranasal delivery minimizes the build-up of
peripheral NGF concentration, even if residual leakage and
absorption of NGF into the blood stream, from the nasal
compartment, has been shown [16,17].
NGF therapeutic window could be further increased if its
nociceptive effects could be avoided altogether. To this aim, we
described a ‘‘painless’’ form of NGF [21], linked to the rare human
genetic disease HSAN V (Hereditary Sensory Autonomic Neu-
ropathy Type V) [22]. In HSAN V patients, a mutation in the
NGFB gene ( exon 3, nt C661T ), changing arginine R100 in
mature NGF to a tryptophan [22], determines the complete loss of
pain perception without affecting most neurological functions [23]
The fact that the NGF mutation R100W appears to separate
the effects of NGF on CNS development from those involved in
the activation of peripheral pain pathways, provides a basis for
designing ‘‘painless’’ NGF variant molecules [7,21,24]. In
particular, we demonstrated that the hNGFR100E mutant
displays a full neurotrophic activity in cultured neurons, while
showing a reduced nociceptive activity in vivo [21], via a selective
alteration of TrkA versus p75NTR binding and signaling [21,24].
In this paper, we characterize a double mutant of human NGF
(hNGFP61S/R100E; Accession number: SPIN000006237) that, in
addition to the pain-related R100E mutation, harbors a second
‘‘tagging’’ P61S mutation [25]. The anti-neurodegenerative
properties of hNGFP61S/R100E protein were assessed in
a disease-relevant primary neuron model, as well as in two animal
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study addresses the question whether the intranasal administration
of NGF-based molecules to Familial Alzheimer Disease-based
mouse models might exert neuroprotection and prevent the
progression of the neuropathological and behavioral deficits.
Results
Design and receptor binding properties of hNGFP61S/
R100E protein
The therapeutic window for NGF in AD would be improved by
the availability of NGF variants that, while retaining neurotrophic
activity, would display a reduced nociceptive activity in vivo
[7,21].
To test whether the administration of recombinant forms of
NGF to APP-based mouse models might exert a neuroprotective
effect and slow the progression of neurodegeneration, we exploited
the double mutant hNGFP61S/R100E (Figure 1).
The design of this mutant was based on the single nucleotide
missense mutation in the NGFB gene, found in Hereditary
Sensory and Autonomic Neuropathy type V (HSAN V) patients
[22], that changes residue R100, in mature hNGF, into a W
residue. We recently showed that the R100 mutation does not
affect hNGF binding affinity for TrkA, while it reduces binding
affinity for p75NTR by two orders of magnitude [24]. It was also
found that R100W hNGF mutants have very similar receptor
binding and signaling properties to an engineered R100E mutant
[21,24], with the latter giving much higher yields, when expressed
and purified from E. coli cells. For this reason, we used the R100E
hNGF mutants for in vivo studies, demonstrating that
hNGFR100E has a nociceptive activity which is much weaker
than that of wild type hNGF [21].
For the present study, the R100E mutation was inserted in the
context of a recombinant form of human NGF ‘‘tagged’’ with
a single residue epitope (hNGFP61S), which replaces the Pro
residue at position 61 of hNGF with Ser residue present in mouse
NGF. hNGFP61S ‘‘tagged’’ molecules are equally bioactive as
hNGF [25] and are selectively detectable against wild type hNGF,
with a specific monoclonal antibody [25].
The resulting double mutant hNGFP61S/R100E was expressed
and purified from E. coli alongside hNGFR100E and hNGFP61S.
The impact of the R100E mutation on binding affinities for the
TrkA and p75NTR receptors is identical whether present in the
context of human NGF or of the ‘‘tagged’’ hNGFP61S similarly
reducing the binding affinity for p75NTR, while preserving the
binding affinity for TrkA identical to that of hNGF or hNGFP61S
[24]. In this study we assess the neurotrophic properties of
hNGFP61S/R100E and its ability to prevent or revert neurode-
generation in different animal models.
Reduced activation of PLC-1c and Erk pathways by
hNGFP61S/R100E
The activation of p75NTR and TrkA signal transduction
pathways by hNGFP61S/R100E was studied in PC12 cells and
primary hippocampal neurons, in comparison to hNGF,
hNGFP61S and hNGFR100E. Beside the state of activation of
TrkA, we decided to analyze downstream signaling pathways that
are involved in NGF-mediated pain transmission and perception
such as TrkA-activated Erk and PLC–1c pathways and p75NTR-
mediated c-jun activation [12,26,27].
The phosphorylation of TrkA residue Tyr490, which activates
the Ras/MAP kinase cascade upon recruitment of ShC (reviewed
in [28]), was largely unaffected by the R100E substitution, being
only slightly reduced in PC12 cells treated with hNGFP61S/
R100E, with respect to hNGF and hNGFP61S (Figure 2A).
Likewise, hNGFP61S/R100E was equally effective as wild type
hNGF, hNGFP61S and hNGFR100E in activating the Akt
pathway (Figure 2B,C). The phosphorylation of residue Tyr 785
of TrkA by NGF leads to PLC-1c recruitment and phosphory-
lation. A significant reduction of PLC-1c phosphorylation was
found after incubation of PC12 cells with hNGFP61S/R100E,
with respect to hNGFP61S and wild type hNGF (Figure 2B,D),
similarly to what observed for the hNGFR100E mutant
(Figure 2B,D). The activation of Erk in PC12 cells was analyzed
with antibodies against active Erk (residues Thr202/Tyr204).
hNGFP61S/R100E, as well as hNGFR100E, significantly reduced
Erk activation, with respect to hNGF and hNGFP61S
(Figure 2B,E).
Binding of NGF to P75NTR triggers the phosphorylation of c-
jun at residue Ser63 (reviewed in [28]. In hippocampal neurons, c-
jun phosphorylation by hNGFP61S/R100E, as well as by
hNGFR100E, determined with a site-specific anti- phospho c-
jun antibody, was reduced by 30% with respect to that induced by
hNGF or hNGFP61S (Figure 2F), consistently with the decreased
binding affinity for p75NTR [24],
Thus, hNGFP61S/R100E shows an overall reduced p75NTR
binding and signaling, and a subtle and selective impairment in the
activation of some TrkA-dependent signalling pathways (notably
PLC-1c and ERK), while other signaling pathways are preserved
(via Shc and Akt). The impact of the R100E mutation is therefore
very similar, in the context of hNGF or of hNGFP61S [24].
Figure 1. Structural localization of the residues Ser 61 and Arg
100 on mouse NGF (PDB: 1BET). The NGF dimer is depicted in blue.
The Ser 61 residues on the two monomers are highlighted in red and
the Arg 100 in green. The cartoon representation was created with
Pymol (http://www.pymol.org). The scaffold of mouse NGF was used for
this figure for illustration purposes, because the loop containing Pro 61
in the human NGF is missing in the available PDB structures. The
mutant human NGF protein used in this study (hNGFP61S/R100E) is
based, instead, on human NGF, in which residue Pro61 is substituted by
its mouse counterpart Ser61, and residue Arg100 is substituted by
Glu100.
doi:10.1371/journal.pone.0037555.g001
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proliferation as well as neuronal survival and
differentiation
The ability of hNGFP61S/R100E to induce cell proliferation,
survival and differentiation was tested in different cellular systems,
in comparison to hNGF, hNGFP61S, hNGFR100E (globally
named hNGF-X).
TrkA-dependent cell proliferation was evaluated in human
erythroleukemia cells TF1, which respond in a dose-dependent
manner to NGF [25,29]. TF-1 cell proliferation provides
a quantitative assay to determine the potency of hNGF mutants.
The proliferation index for hNGFP61S/R100E was similar to that
calculated for hNGF, hNGFP61S, hNGFR100E respectively, all
comprised between 1 and 2 ng/ml (Figure 2G).
Survival curves for chick embryonic DRG neurons [30] exposed
to wild type hNGF or to hNGF mutants were totally superimpos-
able (Figure 2H), as were those obtained when the activity of the
hNGFP61S/R100E mutant was tested in cultures from mouse
dorsal root ganglia (DRG) and superior cervical ganglia (SCG).
Mouse DRG and SCG cultures were first exposed for 4 days to
100 ng/ml of hNGF or of each hNGF mutants (Figure 3A). On
the fifth day, DRG and SCG neurons were deprived of the
corresponding neurotrophin for 24 hours, before cell counting
(Figure 3A) In mouse DRG cultures, the survival efficacy of
hNGFP61S/R100E, was identical to that of hNGF, hNGFP61S
and hNGFR100E (Figure 3B). Likewise, we found that in cultures
of mouse SCG, the survival activity exerted by hNGFP61S/
R100E was identical to that of hNGF, hNGFP61S and
hNGFR100E (Figure 3C).
The neurotrophic and neuroprotective properties of
hNGFP61S/R100E were then assessed in a neuronal NGF-
dependent amyloidogenic model [8], based on hippocampal
neuronal primary cultures. In this model, hippocampal neurons
Figure 2. TrkA and p75NTR signalling by hNGFP61S/R100E. Densitometric analysis of Western blots for (A) TrkA (Y490), (B) Akt (S473), PLC-1c
(Y783), Erks (T204/Y202) and c-jun (S63) phosphorylation, in extracts from PC12 cells, stimulated for 30 minutes with 5 ng/ml of hNGF and hNGF
mutants. Densitometric analysis of Western blots for (C) Akt, (D) PLC-1c,( E) Erks and (F) c-jun. In all blots lanes 1 to 5 refer to untreated, hNGF-,
hNGFR100E-, hNGFP61S/R100E- and hNGFP61S-treated cells, respectively. Values were normalized to total TrkA or actin, as described in the material
and methods section. Graphs are correspond to three independent experiments. (G) Proliferation of human TF1 cells expressing TrkA by hNGF
mutants. The proliferative index was equal to hNGF=1.80; hNGFP61S=1.68; hNGFR100E=1.28 and hNGFP61S/R100E=1.89 (H). The mutant
hNGFP61S/R100E is as effective as hNGF, hNGFR100E and hNGFP61S in inducing survival of chick dorsal root ganglia, after 48 hours exposure. The
experiments were performed in triplicate. Points and Bars represent the mean 6 s.e.m.
doi:10.1371/journal.pone.0037555.g002
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PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37555Figure 3. hNGFP61S/R100E bioactivity on sensory, sympathetic and hippocampal neurons. (A) Experimental scheme of NGF dependence
in mouse dorsal root ganglia and superior cervical ganglia neurons and of hNGF induced survival. The mutant hNGFP61S/R100E is as effective as wild
type hNGF in determining the survival and differentiation of mouse dorsal root ganglia sensory neurons (B) and mouse superior cervical ganglia (C),
after a 4 days exposure. (D) Experimental scheme of induction of NGF dependence in rat hippocampal cells and hNGF induced survival. (E) Exposure
of rat hippocampal cells to hNGF mutants (hNGFX), for 2 days in culture (priming) induces an NGF dependency (cell death after hNGF removal, green
arm), which is rescued by re-exposing the cells to hNGFX (blue and red arms). The mutant hNGFP61S/R100E is equally effective in inducing
dependency after priming and survival of rat hippocampal neurons (total cell counts after counterstaining with 49,6-diamidino-2-phenylindole (DAPI).
(F–K) Deprivation of hNGF (G) and of hNGFP61S/R100E (J) induces caspase 23 activation (arrows), compared to neurons exposed to the
corresponding hNGF mutants (F,I). Exposure to hNGF (H) and hNGFP61S/R100E (K) overcomes the cell death induced by anti-NGF addition. Cells were
counterstained with 49,6-diamidino-2-phenylindole (DAPI) The field is the merge of the two separate channels used to acquire the caspase and the
DAPI images. Scale bar in F–K=50 mm.
doi:10.1371/journal.pone.0037555.g003
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a c–secretase dependent production of Ab, that causes ensuing cell
death [8]. In this system (Figure 3D), rat hippocampal neurons not
‘‘primed’’ with hNGF do not acquire NGF dependency
(Figure 3E). On the contrary, when primed with NGF for 2 days,
hippocampal neurons become dependent on NGF and die in the
absence of NGF (Figure 3E). hNGFP61S/R100E was equally
effective as hNGF, hNGFP61S and hNGFR100E in inducing
priming and NGF dependency, as shown by the equivalent extent
of neuronal death following its removal and neutralization with
anti-NGF antibodies (Figure 3E, F–K). In sister cultures of
hippocampal neurons, primed with each of the hNGF-X
molecules, hNGF, hNGFP61S, hNGFR100E and hNGFP61S/
R100E were equally effective in overcoming the cell death
(Figure 3E, F–K). These results highlight the effectiveness of
hNGFP61S/R100E in a disease-relevant neurodegeneration
model linking neurotrophin deprivation to amyloidogenesis.
Finally, the pro-differentiative capacity of hNGFP61S/R100E
was evaluated in rat PC12 and in human SH-SY5Y cells which are
known to differentiate when incubated with NGF [31]. Priming
and survival of rat PC12 cells induced by hNGFP61S/R100E was
identical to that induced by hNGFR100E and by the positive
controls hNGF, hNGFP61S (Figure S1A, B, C, D, E), both in
terms of time course and of outcome. Notably, in the context of
hNGFP61S the mutation R100E does not even induce the slight
decrease in the number of processes/cell that was observed with
hNGF/R100E, with respect to hNGF or hNGFP61S (Figure S1F).
In human SH-SY5Y neuroblastoma cells [32], hNGFP61S/
R100E was equally effective as hNGF, hNGFP61S, hNGFR100E
in the neurite outgrowth induction (Figure 1G, H, I, J, K).
Thus, we conclude that the priming, survival, pro-differentiative
and neuroprotective activity of hNGFP61S/R100E in different
cell lines and neuronal cultures is identical to that of hNGF,
hNGFP61S and hNGFR100E.
Effect of hNGFP61S/R100E on pain induction
NGF is involved in pain transmission and perception [12]. The
nociceptive activity of NGF is mediated through the activation of
TrkA and p75NTR receptors on sensory nerve endings and of the
corresponding downstream signaling cascades, particularly TrkA-
activated Erk and PLC–1c pathways and p75NTR-mediated c-jun
activation [12,26,27]. Since hNGFP61S/R100E binds p75NTR
with a reduced affinity and shows a selective reduction of some of
the TrkA-mediated signaling cascades involved in pain trans-
mission (such as PLC-1c), we verified whether this protein has
a reduced nociceptive activity, using a paradigm of nociceptive
sensitization by NGF [33]. Mechanical hyperalgesia was measured
in adult CD–1 mice. Since robust interstrain variability was
observed in nociceptive sensitivity, attention was paid the choice of
the correct strain. We decided to use CD-1 mice since they provide
a good nociceptive response, which is more stable than that
observed in other mouse strains [34,35].Mice were intraplantarly
(i.pl.) injected with increasing doses of hNGFP61S/R100E.
Besides saline injection, as a negative control, further controls
were represented by the mutant hNGFP61S, which shows an
overall bioactivity totally super imposable to that of wild type
hNGF [25], and by hNGFR100E, which is characterized by
a strong reduction of pro-nociceptive activity [21]. In the
mechanical allodynia assay, hNGF determines a pain threshold
dose response curve in the range of 0,5 mgt o4mg per injection,
with the dose of 4 mg inducing the maximum variation in pain
threshold [21]. At each dose tested, the hyperalgesic effects are
maximal 5 hours after the injection. In order to compare the
efficacy of hNGFP61S/R100E to that of hNGFP61S and
hNGFR100E, the sub-optimal dose-response range from 1 to
2 mg was explored, which is in the linear range, below the
maximum saturation dose. Hyperalgesia was evaluated at the
5 hour time point. We observed the expected significant increase
in hyperalgesia in hNGFP61S injected mice, at both doses
(Figure 4) as well as the reported significant reduction by
hNGFR100E [21] in elicited hyperalgesic effects (Figure 4), at
both doses tested. hNGFP61S/R100E, at the dose of 2 mg/
injection, showed a reduced hyperalgesic effect (Figure 4.),
comparable to that seen for hNGFR100E, while, unlike the latter,
it showed no difference from hNGFP61S at the lower dose of
1 mg/injection (Figure 4).
We conclude that hNGFP61S/R100E mutant displays a re-
duced effectiveness in nociceptor sensitization and in eliciting
nociceptive responses in mice, with respect to hNGFP61S.
Intranasal delivery of hNGFP61S/R100E prevents learning
and memory deficits and neurodegeneration in aged
anti-NGF AD11 and APPxPS1 mice
The properties demonstrated so far for hNGF R100 mutants in
receptor binding and signaling assays, in different cellular models
and in nociception sensitization in vivo assays [[21,24] and results
in this paper above], justify their prospective use as therapeutic
candidates for neurodegenerative diseases. To this aim, the
effectiveness of the hNGFR100 mutants in the prevention or
rescue of neurodegeneration needs to be tested in adequate models
in vivo. This was done in two different neurodegeneration mouse
models, an NGF deprivation model (AD11 anti-NGF mice) and an
Alzheimer FAD-based model (APPxPS1 mice), in which the cause
of neurodegeneration is not linked to NGF deprivation.
The AD11 model displays progressive memory deficits and
neurodegeneration as a consequence of NGF deprivation, induced
by the expression of anti-NGF antibodies [36,37]. The intranasal
delivery of NGF was previously shown to prevent [18,20] and
rescue [18,25] neurodegeneration in this model and thus it was
used as a standard reference model to assess the biological activity
of the hNGFR100E and hNGFP61S/R100E mutants in vivo.
AD11 mice were treated with hNGF mutants at an age (6 months)
when the progressive neurodegeneration is started, but not yet
fully blown [18]. Two different concentrations of hNGF mutants
(480 and 540 ng/kg, corresponding to 0.45 and 0.51 pmoles/
injection) were chosen. The 0.45 pmole dose was found, in
previous work on NGF delivery to AD11 mice, to be in the right
part of the dose-response curve, corresponding to optimal
pharmacological activity in this model [19], while the 0.51 pmoles
dose was chosen on the basis of the IC50 for hNGFP61S/R100E
in the TF-1 proliferation assay (see Figure 2G).
After two weeks of hNGF treatment, AD11 mice were tested for
visual memory deficits in the object recognition test (ORT), the
first behavioral deficit seen in the progression of AD11
neurodegeneration. Figure S2A describes the experimental vali-
dation of the behavioral assay, showing that all animal groups
spend an equivalent time exploring the objects. AD11 mice treated
with hNGF or the various hNGFR100 mutants showed a complete
and comparable rescue of the memory impairment (Figure 4B,C),
as shown by the longer time exploring the new object, relatively to
the old familiar object.
After the behavioral assessment, mouse brains were evaluated at
the neuropathological level by immunohistochemistry. Saline-
treated AD11 mice displayed a marked reduction in the number of
ChAT-positive neurons in basal forebrain nuclei (Figure 5B,G)
and a typical increase in phosphorylated tau (Figure 6B,G) and
clusters of Ab-positive dystrophic neuritis (Figure 7B,G) with
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described [18,19].
AD11 mice treated with the higher dose of hNGFP61S/R100E
showed a statistically significant increase in the number of ChAT-
positive neurons (Figure 5F,G.), and a concomitant decrease in the
number of phosphotau-positive neurons and of clusters of Ab-
positive dystrophic neurites (Figure 6F,G and Figure 7F,G,
respectively). The efficacy of hNGFP61S/R100E was statistically
indistinguishable from that of a similar dose of hNGF or
hNGFP61S. On the other hand, the mutant hNGFR100E was
less effective than hNGFP61S/R100E, determining only a 50%
increase of the number of ChAT positive neurons at the higher
dose (Figure 5E,G), but no significant effect on the number of
phosphotau-positive neurons (Figure 6E,G) or of Ab-positive
dystrophic neurites (Figure 7E,G).
On the basis of these results, the hNGFP61S/R100E candidate
was selected for further analysis, in a neurodegeneration model not
dependent on NGF neutralization, the APPxPS1 mice (B6C3-
Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J) [38], based on FAD
mutations in APP and PS1 genes (APP gene Swedish mutations
Figure 4. Reduced nociceptive response triggered by
hNGFP61S/R100E and behavioural analysis of painless hNGF-
treated AD11 mice. (A) Mechanical hyperalgesia: reduced hyper-
algesic response 5 hours after intraplantar injection of 1 and 2 mg/
mouse of hNGFR100E and hNGFP61S/R100E compared to hNGF. Bars
represent mean 6 s.e.m. ANOVA plus post-hoc Tukey-Kramer test;
p,0.001. B–C, AD11 mice treated with hNGF or hNGFR100 mutants
show a comparable, and complete, rescue of the memory impairment
observed in saline-treated AD11 mice (B) During the test phase of ORT,
WT mice and AD11 mice treated with different hNGF mutants explore
more the new object than the familiar one. AD11 mice treated with PBS
do not discriminate between familiar and new objects. (C) Discrimina-
tion index showing rescue of the memory deficit in AD11 mice treated
with different hNGF mutants. Bars represent mean 6 s.e.m, ANOVA plus
post-hoc Holm-Sidak test, P,0.05.
doi:10.1371/journal.pone.0037555.g004
Figure 5. Effects of hNGFR100E and hNGFP61S/R100E in AD11
anti-NGF mice. Rescue of the neurodegenerative phenotype
after intranasal delivery of hNGF mutants: Cholinergic deficit:
(A) WT and (B) AD11 mice treated with PBS. AD11 mice treated,
respectively with (C) hNGF (480 ng/kg); (D) hNGFP61S (480 ng/kg) (E)
hNGFR100E (540 ng/kg) and (F) hNGFP61S/R100E (540 ng/kg) Scale
bar=200 mm. (G) Quantification of cholinergic neurons in the medial
septum. Bars represent mean 6 s.e.m, ANOVA plus post-hoc Holm-
Sidak test, P,0.05.
doi:10.1371/journal.pone.0037555.g005
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mice were treated intranasally with hNGFP61SR100E protein
(540 ng/kg, 0,51 pmoles/injection), starting from 10 months of
age for two months. At this age, the APPxPS1mice show no
learning and memory deficits [39] and Ab plaque deposition has
only just started [38]. The design of the hNGFP61SR100E
treatment is therefore addressing a potential preventive efficacy, in
the early phases of the neurodegeneration.
After a two months treatment, spatial learning and memory was
tested in the Morris water maze. First of all, the swimming speed
and distance travelled during the first trial did not differ among the
experimental groups (Figure S2B,C, respectively). PBS treated
APPxPS1 mice showed a clear deficit in spatial learning (Figure 8A)
and memory of the learned task (Figure 8B.). Both deficits were
improved, to levels identical to control littermates, in hNGFP61S/
R100E-treated APPxPS1 mice (Figure 8). The brains were
subsequently analysed at the neuropathological level by immuno-
histochemistry. Ab immunohistochemistry and Thioflavin S
staining confirmed the presence of Ab plaque deposits in the
cortex and hippocampus of PBS treated APPxPS1 mice (Figure 9
B,E,I,L). No Ab plaques were observed in WT transgenic mice
(Figure 9A,D,I,J). Strikingly, hNGFP61S/R100E substantially
reduced the plaque load in the hippocampus and cortex of
APPxPS1 mice (Figure 9C,F, I,J) and determined a shift from
a fibrillar to a more compact morphology of the residual plaques
(Figure 9G,H). The reduction of Ab in hNGFP61S/R100E
treated APPxPS1 mice was confirmed at the biochemical level, by
ELISA, showing a significant reduction of the soluble pools of both
Ab 1–40 and Ab 1–42 with respect to the PBS-treated APPxPS1
mice (relative levels shown in Figure 9K,L).
Figure 6. Rescue of the neurodegenerative phenotype after
intranasal delivery of hNGF mutants in AD11 anti-NGF mice:
Tau hyperphosphorylation. (A) WT and (B) AD11 mice treated with
PBS. AD11 mice treated, respectively with (C) hNGF (480 ng/kg); (D)
hNGFP61S (480 ng/kg) (E) hNGFR100E (540 ng/kg) and (F) hNGFP61S/
R100E (540 ng/kg) Scale bar=200 mm. (G) Quantification of AT8-
positive neurons in the lateral entorhinal cortex. Bars represent mean 6
s.e.m, ANOVA plus post-hoc Holm-Sidak test, P,0.05.
doi:10.1371/journal.pone.0037555.g006
Figure 7. Rescue of the neurodegenerative phenotype after
intranasal delivery of hNGF mutants in AD11 anti-NGF mice: b-
amyloid. (A) WT and (B) AD11 mice treated with PBS. AD11 mice
treated, respectively with (C) hNGF (480 ng/kg); (D) hNGFP61S (480 ng/
kg) (E) hNGFR100E (540 ng/kg) and (F) hNGFP61S/R100E (540 ng/kg)
Scale bar=200 mm. (G) Quantification of Ab-clusters in the hippocam-
pus. Bars represent mean 6 s.e.m, ANOVA plus post-hoc Holm-Sidak
test, P,0.05.
doi:10.1371/journal.pone.0037555.g007
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form of the Ab peptide is represented by oligomeric forms of the
Ab peptide.
Since the anti-Ab antibodies used for immunohistochemistry
and ELISA do not distinguish between monomeric, oligomeric or
fibrillar forms of this peptide, we examined the effect of the
administration of hNGFP61S/R100E on the level of Ab-oligomer.
The commercial polyclonal anti-Ab oligomers antiserum pA11
[40] and a recombinant antibody fragment selective for confor-
mational oligomeric forms of Ab, scFv A13 [41] were used. The
conformational scFvA13 recombinant antibody binds selectively
Ab-oligomers (both mouse and human, and both ADDLs and
natural Ab-oligomers) and shows no binding activity for mono-
meric nor fibrillar Ab [41]. The polyclonal pAb A11 antibody
labels Ab-oligomers in neurons of the cortex (Figure 10B,E) and
hippocampus (Figure 10H,K) of APPxPS1 mice. On the contrary,
no specific labeling was found in WT mice (Figure 10 A,D and
G,J). Interestingly, the treatment with hNGFP61S/R100E signif-
icantly reduced the intracellular staining detected by the A11
antibody (Figure 10C, D, E, F, G, H, I, J, K, L).
Dot blot analysis of brain extracts from PBS-treated and
hNGFP61S/R100E-treated APPXPS1 mice confirmed the effica-
cy of mutant hNGF in decreasing the levels of Ab-oligomers in
transgenic brains (Figure 10M).
Similarly, we found that the scFvA13 antibody specifically labels
Ab-oligomers in the hippocampus (Figure 11B) and cortex
(Figure 11G,I) of APPxPS1 mice, with no specific staining detected
in WT mice (Figure 11A,F) nor in APPxPS1 sections in which the
primary antibody fragment and/or the anti-V5 antibody were
omitted (Figure 11D and E, respectively). Notably, the intranasal
administration of hNGFP61S/R100E strongly reduces both the
intracellular and extracellular staining for Ab-oligomers (Figure 11
C,H,J), with respect to PBS-treated APPxPS1 mice
(Figure 11B,G,I).
To start exploring the mechanism through which NGF reduces
Ab accumulation in APPxPS1 mice, we examined glial cells in the
hippocampus. Indeed, in the hippocampus the majority of TrkA
receptors, besides the TrkA receptors present on basal forebrain
cholinergic terminals, are expressed by glial cells [42]. We
investigated whether the treatment with hNGFP61S/R100E
might modify the microgliosis (Figure 12B,H) and astrocytosis
(Figure 12E; J present in APPxPS1 mice. hNGFP61S/R100E
substantially reduced the number of CD11b (Figure 12C) and
CD45 (Figure 12F) immunoreactive microglial cells and of GFAP-
immunoreactive astrocytes (Figure 12I,J) ) in the hippocampus and
cortex of APPxPS1 mice.
Reduced pErks, c-jun and increased synaptophysin in
APPXPS1 mice treated with hNGFP61S/R100E
Ab oligomers have been shown to activate intracellular signaling
pathways increasing the phosphorylation of Erks [43] and c-jun
[44] and to lead to a reduction of synaptic proteins [45].
To further explore the mechanisms underlying the neuropro-
tective and anti-amyloidogenic effect of hNGFP61S/R100E, we
evaluated by immunofluorescence, the levels of phosphoErks and
phospho-c-jun in CA1 hippocampal neurons from brain sections
from APPxPS1 mice treated with PBS and hNGFP61S/R100E.
Western blot analysis of total Erks did not show any difference
between the different groups of treatment (Fig. 13A,B).
We found that the levels of both phosphoErks (Figure 13F, G,
H) and phospho-c-jun (Figure 13O, P, Q) are much higher in
APPxPS1 mice treated with PBS than in WT mice (Figure 13C, D,
E and L, M, N, respectively for phosphoErks and phospho-c-jun).
Interestingly, in APPxPS1 mice treated with hNGFP61S/R100E
the levels of both phosphoErks and phospho-c-jun were greatly
reduced as in WT mice (Figure 13 I, J, K and R, S, T, respectively
for phosphoErks and phospho-c-jun). Moreover, labeling with an
anti-synaptophysin antibody showed that in APPxPS1 mice
treated with PBS (Figure 13O) there is a decreased expression of
this synaptic marker with respect to WT mice (Figure 13L), which
is fully reverted by the intranasal administration of hNGFP61S/
R100E (Figure 13R).
In conclusion, hNGFP61S/R100E appears to be effective in
providing broad neuroprotection to APPxPS 1 double transgenic
mice, thereby preventing the onset and progression of learning and
memory deficits and reducing the amyloid load in this model. The
neuroprotective effect by recombinant hNGF protein appears to
be exerted at multiple possible levels, by slowing the generation of
Ab peptide and Ab oligomers and by reducing the microgliosis
and astrogliosis, possibly increasing the clearance of Ab peptides,
thereby leading to the observed reduced plaque load.
Discussion
The well documented nociceptive actions of NGF represent
a major drawback for the development of an NGF-based
prospective therapy for human diseases [13,46]. Thus, to develop
NGF for AD therapy, invasive local delivery approaches are being
currently adopted, involving the neurosurgical injection into the
brain parenchyma of cells secreting NGF [14] or of viral particles
harboring hNGF gene [15].
Figure 8. Effect of hNGFP61S/R100E intranasal administration
to APPxPS1 mice: Spatial memory Morris water maze test. Spatial
memory was determined by (A) latency and (B) probe test measures.
P,0.01 in the learning phase by ANOVA followed by post-hoc Holm-
Sidak analysis comparing APPxPS1 treated mice to APPXPS1 treated
with saline.
doi:10.1371/journal.pone.0037555.g008
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37555Figure 9. Effects of hNGFP61S/R100E on Ab plaque load revealed by immunohistochemistry, Thioflavin S staining and ELISA. (A,D)
Absence of Ab plaques in the cortex and hippocampus of WT mice (B,E) Presence of Ab plaques in the brain of APPxPS1. (C,F) The intranasal
administration of 540 ng/kg of hNGFP61S/R100E decreases the plaque load. (G,H) The treatment with hNGFP61S/R100E determined a shift from
fibrillar (G) to more compact morphology of the remaining plaques (H). (I, J) Stereological quantification of plaque load in the cortex and
hippocampus. (K,L) Histograms showing the reduction in the relative levels of soluble (K)A b1–40 and (L)A b1–42 in APPxPS1 brains after treatment
with hNGFP61S/R100E. Points and bars represent mean 6 s.e.m. ANOVA followed by post-hoc Holm-Sidak analysis: P,0.05. Scale bars in A–
F=1000 mm. Scale bars in G–H=50 mm.
doi:10.1371/journal.pone.0037555.g009
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to improve its therapeutic window, by increasing the access of
NGF to CNS target regions, while limiting its off target, pain-
inducing actions [7].
The intranasal delivery option provides a promising solution
towards the former objective. Indeed, efficacy of intranasal NGF
delivery [17] to rescue neurodegeneration in animal models has
been demonstrated [18,19,20]. As to whether and how the pain
inducing activities of NGF can be reduced or eliminated by this
delivery route remained an open problem, since passage of NGF
into the blood stream, from the nasal compartments, has been
shown [16,17]. NGF therapeutic window could be further
increased if its nociceptive effects could be avoided altogether.
In this paper, we characterize a recombinant NGF variant that,
while displaying a full neurotrophic and anti-amyloidogenic
activity, also shows a reduced nociceptive activity. The
hNGFP61S/R100E molecule combines a P61S tagging mutation
[25], with the R100E mutation, designed to selectively reduce the
pain sensitizing activity of NGF, while retaining its neurotrophic
properties [21,24]. On the hNGFP61S backbone, a second
mutation was inserted at position R100, inspired by the genetic
mutation found in NGFB gene in HSAN V patients, which
changes the basic R100 in mature NGF to a non-polar
tryptophan, and is responsible for the decreased perception of
pain in these patients [22]. In recent studies we showed that the
clinical phenotype of HSANV can be, at least in part explained by
a selective inability of hNGF R100 protein to activate nociception,
while retaining the neurotrophic properties [21]. Indeed, the
binding affinity of hNGFR100 mutants to p75NTR is strongly
reduced, while that for TrkA remains unchanged [21,24]. Despite
the identical TrkA binding affinity, hNGFR100 mutants differ
from hNGF in their ability to activate downstream TrkA-
dependent signalling pathways, with a notable selective reduction
in the ability to activate PLC–1c and Erks [21]. Notably,
hNGFR100 mutants do not sensitize nociceptors and fail to
induce pain in vivo [21]. Thus, hNGFR100 mutants may share
some properties of other NGF mutants described to be selective
TrkA agonists with respect to p75NTR [47], but have the
additional property of selectively modulating a subset of the
signaling pathways downstream of TrkA, and to be proven as less
potent nociception activators.
On the basis of these properties, the hNGFP61S/R100E
therapeutic candidate was designed, aimed at optimizing the
therapeutic window for NGF. The characterization of the
hNGFP61S/R100E double mutant is provided in this paper.
Moreover, until recently [48] no study addressed the issue whether
administration of NGF, or of NGF-related molecules, might affect
the neurodegeneration in FAD related APP mouse models.
We show that hNGFP61S/R100E is characterized by a reduced
ability to activate PLC–1c, Erks and c-jun, providing a molecular
explanation for the reduced pro-nociceptive activity, observed in
a mechanical allodynia pain model. hNGFP61S/R100E showed
no difference with respect the hNGF counterparts in a number of
different survival, differentiation and proliferation cellular assays.
Thus, hNGFR100P61S/R100E maintains the neurotrophic sig-
naling stream unchanged, while showing a reduced signaling
involved in nociceptor sensitization and pain perception. Notably,
hNGFP61S/R100E is very effective to rescue or prevent
neurodegeneration and learning and memory deficits in mouse
models, including an APP-based model, in which the neurode-
generation is not directly caused by NGF inhibition.
Figure 10. Decreased Ab oligomer immunoreactivity in
APPxPS1 mice after treatment with hNGFP61S/R100E: poly-
clonal pAb A11 antibody. (A) Parietal cortex and (G) hippocampus
of WT mice treated with PBS. Enlargements are shown in D and J,
respectively. (B) Cortex and (H) hippocampus of APPxPS1 mice treated
with PBS. Enlargements are shown in E and K, respectively. (C) Cortex
and (I) hippocampus of APPxPS1 mice treated with PBS. Enlargements
are shown in F and L, respectively. (M) Dot blot analysis of brains
extracts from WT (row 1,2), APPxPS1 (rows 3,4) and APPxPS1 mice
treated hNGFP61S/R100E (rows 5,6) probed with the A11 (row 1,3,5)
and anti-tubulin (rows 2,4,6) antibodies. The image is representative of
4 independent experiments. Scale bars in A–B, G–I=200 mm. Scale bars
in D–F, J–L=50 mm.
doi:10.1371/journal.pone.0037555.g010
Figure 11. Decreased Ab oligomer immunoreactivity in
APPxPS1 mice after treatment with hNGFP61S/R100E: scFV
A13 antibody. Hippocampus from (A) WT mice treated and (B)
APPxPS1 mice treated with PBS and (C)A P P x P S 1t r e a t e dw i t h
hNGFP61S/R100E mice. In D,E, images from sections from APPxPS1
mice treated with PBS and used as experimental controls in which the
primary antibody was omitted and sections were incubated only with
the antibodies against the (D) SV5 tag and the biotinylated anti-rabbit
antibody. In (E) the antibody against SV5 was also omitted from the
incubation. In F–H, A13 labeled sections from the cortex of (F) WT mice
treated and (G) APPxPS1 mice treated with PBS and (H) APPxPS1
treated with hNGFP61S/R100E mice. In I and J, Enlargements of Ab
oligomers immunoreactivity in (I) APPxPS1 and in (J) APPxPS1 mice
treated with hNGFP61S/R100E. Scale bars in A–H=100 mm; scale bar in
I–J=30 mm.
doi:10.1371/journal.pone.0037555.g011
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respect to hNGFR100E, in rescuing the neurodegeneration in the
AD11 model, as well as a slight difference between the R100E and
the P61S/R100E NGF proteins in nociceptive sensitization assays,
most likely involving a structural cross-talk between S61 and R100
residues. Thus, the P61S substitution, which per se does not
determine any measurable influence, compared to wild type NGF
(Covaceuszach et al 2009), , could exert a long distance influence
on the residue at position 100. In all the available 3D structures of
hNGF complexes [49,50,51] loop 58–68 (CRDPNPVDSGC) is
only partially resolved. Indeed the region 61–66 (PNPVDS),
including the residue P61, is structurally not defined. On the
contrary, in the crystal structures of mouse NGF (mNGF) [52,53]
the homologous loop (CRASNPVESGC), including S61, is
structurally well defined. Thus, the 58–68 loop in hNGF has
likely a higher intrinsic conformational flexibility compared to
mNGF. This loop is structurally positioned over the C58–C108
and C68–C110 cysteine knot, and it may pose structural
constraints on the possible conformations taken by the disulphide
bridges of the cysteine knot. The C58–C108 and C68–C110
disulphide bridges pair b-strand-2 to b-strand-4. Residue R100 is
located at the N-term of b-strand-4 (carrying C108 and C110).
The P61S substitution in hNGF, by rendering the 58–68 loop
structurally similar to that observed in mNGF, might cause a local
conformational change in the proximity of the interacting cysteine
knot, thereby exerting a long-distance effect on R100, which could
explain the observed subtle modifications in the functional effects
of this mutation in the context of hNGF or of hNGFP61S.
The neuroprotective and anti-amyloidogenic properties of
hNGFP61S/R100E mutant demonstrated in APPxPS1 transgenic
mice are noteworthy. In this mouse model, the expression of
mutated human APP and PS1 is the first cause of neurodegenera-
tion. The administration of hNGFP61S/R100E was performed at
an age when memory deficits have not yet started [39] and
amyloid plaque deposition is in the initial phase [38]. This allowed
to study the effects of hNGFP61S/R100E at very early stages of
the progressive neurodegeneration, showing that in APPxPS1 the
hNGFP61S/R100E mutant was able to prevent learning and
memory defects and to greatly reduce Ab deposition. In addition,
by using a conformation specific antibody anti-Ab oligomers [41],
we demonstrated that hNGFP61S/R100E prevents or reduces the
accumulation of Ab oligomers, considered the earliest and most
synaptotoxic forms of Ab. Thus, hNGFP61S/R100E exerts an
anti-amyloidogenic effect in vivo, in a disease-relevant FAD-based
model. From a mechanistic point of view, this might involve
a generalized neuroprotective activity by the neurotrophin, at
multiple levels, by slowing the generation of Ab peptide and Ab
oligomers, by reducing the microgliosis and astrogliosis and/or,
possibly, by increasing the clearance of Ab peptides, thereby
leading to the observed reduced plaque load and Ab oligomer
levels. The observed effects on astrocytes and microglia are
consistent with both these cell types expressing TrkA and p75NTR
NGF receptors, in normal and pathological conditions [54,55,56].
Reactive astrocytes, present in APP xPS1 brain due to amyloid
pathology, also express higher levels of TrkA in human AD
[57,58]. We found a reduction of both microgliosis and
astrocytosis in hNGFP61S/R100E treated APPxPS1 brains,
suggesting that the ensuing reduced neuroinflammation might
contribute to remove an environment permissive for the buildup of
amyloid pathology and neurodegeneration. Further studies are
required to verify whether the activation of TrkA signaling by
hNGFP61S/R100E might regulate the known mechanisms of
internalization and Ab degradation by astrocytes [59,60].
The selective modulation of TrkA and p75NTR downstream
signaling pathways might also contribute to the neuroprotective
action of hNGFP61S/R100E. Indeed, while the activation of the
Akt signaling pathway, which is preserved by hNGFR100
mutants, is required for a neuroprotective action and is down-
regulated by soluble Ab oligomers [61], Erks and c-jun activation
have been linked to neurodegeneration and cell death. Oligomeric
assemblies of Ab have been found to up-regulate phospho-Erks
[62], which, in turn, can lead to abnormal phosphorylation of tau,
generation of dystrophic neurites and progressive neuronal
degeneration [43,63,64]. Similarly, up-regulation of c-jun has
been linked to cell death and tau phosphorylation in AD [65], and
its down-regulation prevents the amyloidogenic cleavage of APP
and the formation of amyloid plaques in AD mouse models [44].
Thus, the decreased activation of Erks and c-jun by hNGFP61S/
R100E would uncouple their involvement in a positive feedback
neurodegenerative loop and facilitate the down-regulation of the
effects by the aberrant APP processing. Further studies are
Figure 12. Reduced microgliosis and astrocytosis in APPxPS1
mice after intranasal hNGFP61S/R100E treatment. Absence of
(A,D) microgliosis (revealed with anti-CD11b and anti-CD45 antibodies)
and (G) astrocytosis (revealed with anti-GFAP antibodies) in the
hippocampus of WT mice. Presence of (B,E) microgliosis and (H)
astrocytosis in the brain of APPxPS1. The administration of hNGFP61S/
R100E decreases (C,F) microgliosis and (I) astrocytosis. Images in A–C
and D–F were obtained after incubation with the anti-CD11b and anti-
CD45 antibodies, respectively. (J) Quantification of astrogliosis. Bars
represent mean 6 s.e.m. ANOVA followed by post-hoc Holm-Sidak
analysis: P,0.05. Scale bars in A–F=50 mm. Scale bars in G–I=100 mm.
doi:10.1371/journal.pone.0037555.g012
Painless NGF Slows Neurodegeneration in FAD Mice
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e37555required at more later stages of neurodegeneration, when
conflicting results about the ‘‘benefits’’ of Erks activation have
been reported [66].
The possibility of hNGFP61S/R100E acting directly on APP
processing and its direct consequences, such as the vicious cycle
linking Ab to the proNGF/NGF balance [67,68] should also be
considered for future investigation. In this respect, it should be
noted that APPxPS1 mice show a defect in NGF retrograde axonal
transport by cholinergic neurons, as a consequence of APP over-
expression [69]. Even if this defect does not lead to overt
cholinergic deficit, administration of NGF might provide a boost
to cholinergic function which may contribute to limiting the
negative consequences of the abnormal APP processing. In any
event, our results unequivocally show that this hNGF variant can
exert broad neuroprotection and prevent neurodegeneration
originated by FAD linked mechanisms. Moreover, the results
provide additional evidence for the tight links between the
pathological processes observed in FAD-based mouse models
and in anti-NGF mouse models [70], and add the evidence that
TrkA agonists can improve learning and memory deficits in APP
mice [48].
In conclusion, our results provide a strong rational basis for the
development of ‘‘painless’’ NGF variant for therapeutic applica-
tions. The hNGFP61S/R100E property has the dual property of
being traceable with respect to human NGF, via the substitution
P61S [25], and of having a greatly reduced pain sensitization
activity on sensory fibers, while displaying an identical neuro-
trophic activity as hNGF. These properties make hNGFP61S/
R100E an ideal candidate for the development of a noninvasive
therapy for AD, avoiding the need for localized delivery by direct
injection of engineered cells or of viruses into the brain
parenchyma. The reduced pain sensitizing actions will allow
higher doses to be delivered through intranasal delivery, and reach
the target areas in the CNS while keeping the peripheral
concentrations of NGF below the threshold for nociception.
Figure 13. Reduced activation of phospho-Erks and p-c-jun and increased synaptophysin staining in APPxPS1 mice treated with
hNGFP61S/R100E. (A) Western analysis of soluble brain extracts from WT, APPxPS1 and painless hNGF-treated APPxPS1 mice. Blots were probed
with anti-Erks (upper panel) and mAb anti-tubulin YOL1 (lower panel). Lanes 1–3 refer to WT mice, lanes 4-6 to APPxPS1 mice treated with PBS and
lanes 7–9 to APPxPS1 mice treated with hNGFP61S/R100E. (B) The graph reports quantitative determinations of the intensities of relevant bands. C–
K, Immunofluorescence for MAP2 and pErks in WT mice (C–E), APPxPS1 mice treated with PBS (F–H) and (I–K) APPxPS1 mice treated with hNGFP61S/
R100E (61/100). L–T, Immunofluorescence for synaptophysin (SYP) and pErks in WT mice (L–N), APPxPS1 mice treated with PBS (O–Q) and (R–T)
APPxPS1 mice treated with hNGFP61S/R100E (61/100). Scale bar=25 mm.
doi:10.1371/journal.pone.0037555.g013
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Transgenic mice
Six-months old C57BL6SSJL AD11 anti-NGF mice were
produced by breeding single transgenic AD11-VH and AD11-VK
mouse lines, as described [37]. Wild type (WT) mice were obtained
by crossing non transgenic littermates of AD11 mice.
B6 transgenic mice expressing human PS1 gene, harboring the
familial AD-linked A246E mutation and a chimeric mouse/
human APP695gene, harboring a human Ab domain with
mutations (K595N and M596L) linked to Swedish familial AD
pedigrees (APPswe), were purchased from Jackson Labs (Bar
Harbour, ME). Non transgenic littermates were used as wild type
(WT) control mice.
Mice were kept under a 12 hours dark to light cycle, with food
and water ad libitum. Experiments were performed according to the
national and international laws for laboratory animal welfare and
experimentation (EEC council directive 86/609, OJ L 358, 12
December 1987).
hNGF mutants expression and purification
hNGF mutant expression and purification were performed as
previously described [24]. Briefly, hNGF mutants were expressed
in E. coli as unprocessed proNGF, refolded in vitro from inclusion
bodies, and mature NGF was obtained from in vitro-refolded
proNGF, by controlled proteolysis, followed by chromatography
[24].
In vitro phosphorylation signaling assays
Rat PC12 pheochromocytoma cells [71] and primary cultures
of hippocampal neurons [72] were used to assess NGF receptor
activation and signaling, after incubation with hNGF or hNGF
mutants. PC12 cells were cultured as described [21]. To evaluate
the activation of signaling pathways, PC12 cells were incubated for
30 minutes in the presence of 5 ng/ml of the corresponding
hNGF mutant. Hippocampal neurons were prepared from rat
embryos (embryonic day 17–18 (E17–18)), from timed pregnant
Wistar rats (Charles River Laboratories Italia, Calco, Italy). The
hippocampus was dissected out in Hanks’ balanced salt solution
buffered with Hepes and dissociated via trypsin/EDTA treatment.
Cells were plated at 1610
6 cells on 3.5-cm dishes pre-coated with
poly-DL-lysine. After 2 days of culturing in Neurobasal medium
with B-27 supplement and glutamax (Invitrogen), cytosine
arabinofuranoside was added to reduce glial proliferation. Half
of the medium was changed every 3–4 days. Neurons were
incubated with hNGF or hNGF mutants (100 ng/ml) for 30 min
3–5 days after plating. PC12 cells and hippocampal neurons were
lysed in cold RIPA buffer supplemented with phosphatase and
protease inhibitors (50 mM Tris pH 7.4, 150 mM NaCl, 1%
Triton X100, 1% Na deoxycholate, 10 mM EDTA, protease
inhibitor cocktail (Roche Applied Science, Penzberg, Germany),
1 mM sodium orthovanadate, 50 mM NaF, 100 nM okadaic
acid). Insoluble material was removed with a 5 min, 10,000 rpm
centrifugation. The extracts were quantified using the Lowry test
(Bio-Rad, Hercules, CA ) and normalized in the subsequent assays.
PC12 and hippocampal neuron extracts were processed for
Western blot analysis as described before [21]. The following
primary antibodies were used: anti-phosphotyrosine 490 TrkA
antibody (Cell Signaling Technology, Danvers, MA; diluted
1:1000), anti-phosphoserine 476 Akt antibody (Cell Signaling
Technology, diluted 1:1000), anti-phosphotyrosine 783 PLC-1c
antibody (Cell Signaling Technology, diluted 1:1000), anti-
phosphothreonine 202/phosphotyrosine 204 Erk1/2 antibody
(Cell Signaling Technology, diluted 1:1000), anti phosphoserine
63 c-jun antibody (Cell Signaling Technology, diluted 1:500) and
anti-TrkA antibody (R&D Systems Inc., Minneapolis, MN; diluted
1:1000). The intensities of the immunoreactive bands were
quantified and analyzed by using the National Institutes of Health
(NIH) image analysis program ImageJ 1.44P after normalizing for
protein content, evaluated by the intensity of total TrkA band in
the case of phospho- TrkA or actin (Sigma-Aldrich, clone AC-40,
diluted 1:1000) in the case of the other signaling proteins.
In vitro survival, proliferation and neurotrophic assays
TF1 cell proliferation assay. TF1 cells (ATCC-LGC
Standards, Teddington, UK) assay was performed as described
[21,29]. Methodological details are provided in Methods S1.
PC12 cell and SH-S5SY differentiation assays. Culturing
conditions and incubation protocol with hNGF mutant are
described in Methods S2.
Hippocampal cell neurodegeneration assay. In this sys-
tem, rat hippocampal neurons are rendered NGF-dependent by
incubation with NGF for two days, after which, upon removal of
NGF and addition of anti-NGF antibodies, cells activate aberrant
amyloidogenesis that causes Ab peptide-dependent cell death [8].
Hippocampal neurons were prepared as described above. Neurons
were primed by exposing them to hNGF or hNGF mutants
(50 ng/ml) for 48 h at 3–4 days after plating, washed 3 times with
the medium and incubated for additional 48 h in presence of the
anti-NGF monoclonal antibody aD11 [73] (10 mg/ml) or of anti-
NGF plus the same mutant (50 ng/ml) used during the priming.
Viable hippocampal neurons were quantified by counting the
number of intact nuclei. The presence of cell death was revealed
by active caspase-3 immunoreactivity, incubating cells with the
anti-active caspase 3 antibody (1:100, Cell Signaling Technology).
Cells were counterstained with 49,6-diamidino-2-phenylindole
(DAPI).
DRG and SCG neurons survival assay. Chick embryonic
dorsal root ganglia (DRG) (E6–E9) were collected, cleaned,
trypsinized, dissociated and cultured in the absence or presence
of hNGF mutants (0,1–10 ng/ml) as described [30]. Mouse
superior cervical ganglia (SCG) and DRG were dissected from
postnatal day 3 C57BlxSJL mice, enzymatically dissociated, and
plated on 48 wells culture dishes. Neurons were maintained in
DMEM supplemented with fetal bovine serum (10%), penicillin
(1 U/ml), streptomycin (1 U/ml), and hNGF or hNGF mutants
(100 ng/ml). After 4 days, a subset of neurons were washed and
incubated in culture medium without the addition of neurotro-
phins for 48 hours. Neurons were lysed and cell counts performed.
In vivo NGF-induced nociceptive assays
CD1 male mice, weighing 40–45 g, from Charles River Labs
(Como, Italy) were used for nociceptive tests. Different groups of
mice were used for mechanical allodynia behavioral testing. The
pro-nociceptive inducing activity of hNGFP61S/R100E was
compared to that of hNGFP61S and of hNGFR100E. Mice were
intraplantarly (i.pl.) injected, on their hindpaws’ plantar surface,
with 20 ml of hNGF, hNGFP61S, hNGFR100E or hNGFP61S/
R100E at concentrations corresponding to 1 and 2 mg/20 ml/
mouse in saline 0.9% NaCl. From previous studies with
hNGFR100E, these concentrations are in a linear dose-response
range below the maximum saturation dose [21]. Control mice
were injected with 20 ml of saline. Mechanical allodynia was
measured 1 hour before (baseline) and 1, 3, 4 and 5 hours after
i.pl. injections, as described [21].
All experiments were conducted according to national and
international laws for laboratory animal welfare and experimen-
tation (EEC Council directive 86/609, OJ L 358, 12 December
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Intranasal delivery of hNGF mutants. In AD11 mice, the
intranasal administration of hNGF mutants was performed on
mildly anesthetized mice, as previously described [20], in a number
of 8–10 mice per group. hNGF mutant doses of 480 ng/kg for and
540 ng/kg were used. The dose range was chosen to cover the
potency range of R100E mutants, as determined in the
quantitative TF1 proliferation cellular assay. hNGF was used only
at the dose of 480 ng/kg. In APPxPS1 mice, the modality of
administration was the same, except for the omission of the
anesthesia, since preliminary data showed a reduced resistance of
these mice to repeated intraperitoneal administrations of the
anesthetic. It should be taken into consideration that anesthesia, in
AD11 mice, is a practical precaution, to restrain the mice during
the intranasal administration and optimize the delivery. The
experimental protocol was approved by Italian Department of
Health (approval n. 1/2011).
The mutants were diluted in 1 M phosphate-buffered saline
(PBS, pH 7.4) at a quantity of 0.45 and 0.51 pmoles respectively
for the doses of 480 ng/kg and 540 ng/kg, and were administered
intranasally to mice, 3 ml at a time, alternating the nostrils, with
a lapse of 2 min between each administration, for a total of 14
times. During these procedures, the nostrils were always kept
open. As control treatments, AD11 and APPxPS1 mice were
treated with PBS. The frequency of administration for intranasal
delivery was three times per week (every 2 days). WT mice treated
with PBS were used as a control group. Administrations were
repeated for 7 times, over a 15 days period.
Object recognition test
The visual object recognition test was performed as described
before [19], Details are provided in Methods S3.
Morris water maze
Morris water maze was used to establish whether aged
APPxPS1 mice treated with the hNGFP61S/R100E showed an
amelioration in spatial memory deficits. A circular water tank,
made of aluminum (diameter, 120 cm; height, 40 cm) was filled to
a depth of 25 cm with water (23uC 6), rendered opaque by the
addition of a small amount of milk powder. Four positions around
the edge of the tank were arbitrarily designated north (N), south
(S), east (E), and west (W), which provided four alternative start
positions and also defined the division of the tank into four
quadrants: NE, SE, SW, and NW. A circular clear Perspex escape
platform (diameter, 10 cm; height, 2 cm) was submerged 0.5 cm
below the water surface and placed at the midpoint of one of the
NE quadrant. Mice were trained with four trials per day for 4 days
(with an inter trial interval of 30 min). The start position (N, S, E,
or W) was pseudo-randomized across trials. Mice were allowed up
to 60 sec to locate the escape platform, and their escape latency
was recorded. On the fifth day, the fourth trial was substituted by
a probe trial, during which the escape platform was removed from
the tank, and the swimming path of each mouse was video-
recorded over 60 sec, while it searched for the missing platform.
Determination of soluble Ab1–40 and Ab1–42. The
analysis was performed on soluble brain extracts using the Brain
ELISA test kit (Millipore). Tissues were processed according to the
manufacturer instructions. The values for APPxPS1 mice and
APPxPS1 mice treated with hNGFP61S/R100E were normalized
against the corresponding values obtained from WT brain
extracts.
Western blot analysis. Brain extracts were analyzed by
SDS/PAGE (10% polyacrilamide gels) and western blot (WB).
Nitrocellulose membrane were probed with the antibodies against
Erks 42/44 (Santa Cruz) and, after stripping, with the anti-tubulin
monoclonal antibody YOL-1 (kindly provided by Cesar Milstein,
MRC Laboratory of Molecular Biology, Cambridge, UK). The
intensities of the immunoreactive bands were quantified and
analyzed by using the National Institutes of Health (NIH) image
analysis software (NIH IMAGEJ) after normalizing for protein
content, evaluated by the intensity of the tubulin band with mAb
YOL-1.
Dot blot analysis was performed by spotting on nitrocellulose
membrane increasing amounts of soluble extracts corresponding
to 3.5, 7 and 15 mg of protein. Incubation was performed with
pAb A11 (Millipore) diluted 1:1000 in 5% skimmed milk/PBS plus
0.1% Tween 20.
Histological and neurostereological analysis
After behavioral analysis, mice were anesthetized with an excess
of 2,2,2-tribromethanol (400 mg/kg) and intracardially perfused
with a 4% solution of paraformaldehyde in PBS. Brains were
processed for immunohistochemical analysis as described before
[36,74]. The following primary antibodies were used: goat anti-
choline acetyltransferase (ChAT;1:500, Millipore, Billerica, MA);
goat anti-NH2 terminus of Ab (1.100; Santa Cruz, Santa Cruz,
CA); mouse anti-b amyloid clone 6E10 (1:250; Sigma, St Louis,
MO, for APPxPS1 mice only) and mouse anti-human phosphotau
recognizing Ser199 (1:10 clone AT8; Pierce Endogen, Rockford,
IL); mouse anti-GFAP (1:1000 clone G-A-5; Sigma); goat anti-
CD45 and CD11b (1.100; Santa Cruz, Santa Cruz, CA); anti-
phosphothreonine 202/phosphotyrosine 204 Erk1/2 antibody
(1:100, Cell Signaling Technology), anti phosphoserine 63 c-jun
antibody (1:100, Cell Signaling Technology); anti-microtubule-
associated protein 2a+b (1:100, Sigma); anti-synaptophysin (1:100,
Santa Cruz). For double immunofluorescence, chicken AlexaFluor
488anti-rabbit antibodies and donkey AlexaFluor555 anti-mouse
antibodies were used. Brains from APPxPS1 mice were also
incubated with the rabbit polyclonal antibody directed against the
C-terminus of b amyloid 1–42 (1:500, Millipore, Billerica, MA).
The Thioflavin S assay was performed by incubating section with
a 0,5% Thioflavin S solution.
The detection of Ab oligomers in brain sections was performed
using the anti-Ab oligomer polyclonal antiserum pAb A11 and the
sequence and conformational specific antibody scFv A13 [41].
Incubation with the polyclonal antibody A11 was carried out at
a 1:1000 dilution. When scFv A13 was used to reveal Ab
oligomers, sections were incubated with 0.1 mg/ml of the scFv A13
antibody, followed by the anti-V5 antibody (Sigma, 1:500) against
the c-terminal tag on scFv A13 and a biotinylated anti-rabbit
antibody (Vector) in presence of 30% Fetal bovine serum (FBS). At
the end of the immunohistochemical procedures, neurostereolo-
gical analysis was performed as described before [19].
Astrogliosis was evaluated by measuring the intensity of GFAP
staining in the hippocampus, after keeping fixed the condition of
microscope illumination, with the anti-GFAP antibody clone G-A-
5.
Statistical Analyses
Statistical analyses were performed using the Sigmastat v. 3.11
program (Systat Software, San Jose, CA). The alpha was set at
0.05 and a normality and equal variance test were first performed.
All values of behavioral tests to assess nociception are expressed
as mean 6 s.e.m of 8–10 animals per group. Two-way ANOVAs
for repeated measures were used to analyze the effects of
pharmacological treatments. Post-hoc comparisons were carried
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Supporting Information
Figure S1 Survival and differentiation of PC12 and SH-
SY5Y cells by hNGFP61S/R100E. In panels A–E, PC12 cells
were primed with 50 ng/ml of hNGF (B), hNGFP61S (C),
hNGFR100E (D) or hNGFP61S/R100E (E) for 1 week and
replated for 2 days in presence of 10 ng/ml of either hNGF or the
respective mutant. Negative controls (A) are represented by cells
incubated in absence of hNGF or hNGF mutants. (F) Quantifi-
cation of the number of PC12 processes after exposure to the
different neurotrophins. (G) Untreated human neuroblastoma SH-
SY5Y cells are induced to differentiate when treated for 7 days
with 100 ng/ml of hNGF (H), hNGFP61S (I), hNGFR100E (J) or
with hNGFP61S/R100E (K). Bars represent the mean 6 s.e.m. *,
P,0,05 versus hNGF.
(TIF)
Figure S2 Effect of hNGFP61S/R100E intranasal ad-
ministration to AD11 and APPxPS1 mice: validation
controls for behavioral experiments. (A) WT, AD11 mice
treated with PBS and AD11 mice treated with hNGF or
hNGFR100 mutants show comparable exploration times during
the sample phase of the ORT. (B, C) Morris water maze test in
APPxPS1 mice. Mice from all genotypes show an equal
performance in terms of (A) swimming speed and (B) distance
covered during the first trial on the first day
(TIF)
Methods S1 TF1 cell proliferation assay.
(DOCX)
Methods S2 PC12 cell and SH-S5SY differentiation
assays.
(DOCX)
Methods S3 Object recognition test.
(DOCX)
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